5th World Congress on Cancer Therapy
Jiangsu Andeson Biomedical Inc., China
Title: Anti-tumor activity of Wei-Shen: Pre- Clinical and clinical studies
Biography: Yuguo Yu
Background: Gastric cancer (GC) is the second leading cause of cancer deaths worldwide. China accounts for over 40% of all new GC cases in the world. Currently the overall 5 year relative survival rate of GC remains poor. New approaches to treat gastric cancer are needed. Wei-shen, a complex prescription based on the theory of Traditional Chinese Medicine (TCM), has shown signifi cant effi cacy on GC patients in private practices. In this report, the anti-tumor activity of Wei-Shen was evaluated in both pre-clinical and clinical studies. Methods: A prospective, open label observational study was conducted to investigate the eff ectiveness of Wei-Shen on gastric cancer patients. Th e drug was administered in capsules containing 3g raw powder of Wei-Shen BID for 3 to 6 months. Th e cytotoxicity study was conducted using a serial of dilutions of ethanol extract of Wei-Shen powder on the cultured KATO III gastric, HT29 and HCT15 colorectal and PC-9 lung cancer cells. Results: Total of 38 GC patients were enrolled in the study and treated with Wei-Shen for 3 to 6 months. Among them, complete remission was achieved in 30 patients, whose tumors disappeared in biopsy tests. Some GC patients have disease free survival for over 10 years aft er being treated Wei-Shen for 3 to 21 months. Th e treatment of 95% ethanol extract of Wei-Shen for 24-96 hr had dose-dependent anti proliferative or killing eff ects on cultured KATO III gastric cancer cells. Th e Wei-Shen extract had similar anticancer eff ects on HT29 and HCT15 colorectal, and PC9 lung cancer cells. Conclusion: Traditional Chinese Medicine holds great potential to improve people’s health and wellness. Wei-Shen demonstrated potent effi cacy in gastric cancer patients and complete remission was achieved in subset of patients. Wei-Shen has dramatic cytotoxicity on highly malignant gastric cancer, colorectal and lung cancer cell lines. Further research is needed to elucidate the mechanisms of Wei-Shen’s anti-cancer eff ect. Th e effi cacy and safety of Wei-Shen need to be further investigated in large-scale, placebo-controlled clinical trials.